IGC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IGC Pharma Inc is not a strong buy for a beginner, long-term investor at this time. While the technical analysis shows some positive momentum, the financial performance is weak, and there are no significant catalysts or trading signals to support a strong entry point. Holding off on investment until clearer growth trends or catalysts emerge is recommended.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI of 83.423 suggests the stock is overbought. Moving averages are converging, showing indecision. Key resistance levels are at 0.321 and 0.338, with support at 0.294 and 0.267.
The MACD indicates bullish momentum, and there is a 70% chance of minor price increases in the next day, week, and month.
The RSI indicates the stock is overbought, and there are no significant hedge fund or insider trading trends. Additionally, there is no recent news or congress trading data to act as a catalyst.
In 2025/Q4, revenue increased by 18.64% YoY to $350,000. However, net income dropped by 74.84% YoY to -$726,000, EPS fell by 75% YoY to -0.01, and gross margin declined by 78.32% YoY to 12.57%. Overall, the financials show weak profitability and growth.
No analyst ratings or price target changes are available for IGC Pharma Inc.
